Go to Health Care Provider version
| Diagnosis | Glioblastoma, Astrocytoma, Oligodendroglioma, Mixed Glioma, Pleomorphic Xanthoastrocytoma, Ganglioglioma, DIPG, Ependymoma | Study Status | Closed to enrollment |
| Phase | I/II |
| Age | Child, Adult - (10 years to 25 years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | CLR 131 administered intravenously, fractionated dose
Arm 1: two planned cycles, 20 mCi/m2 on day 1 and day 15
Arm 2: three planned cycles, 10mCi/m2 on day 1 and day 15 |
| Last Posted Update | 2025-04-16 |
| ClinicalTrials.gov # | NCT03478462 |
International Sponsor
Cellectar Biosciences, Inc.Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel MorgensternCentres
Study Description
This clinical trial studies the side effects of a medication called CLR131. This medication is a targeted radiopharmaceutical, which means it acts like radiation therapy, but is given intravenously as an infusion.
CLR 131 is designed to target cells with cancer rather than cells without cancer. The main goal of this study is to determine what is the safe amount of medication to give to children with cancer that has come back or is not responding to treatment.
Inclusion Criteria
- Age between 10 and 25 years
- High Grade Glioma that has come back (relapse) or not improved despite treatment (progression)
- Must meet all bloodwork requirements
- Patient must be up and about at least 60% of their waking hours
- Patient must be willing to comply with study visit requirements and sign a consent form
Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
